

# BIOCARTIS GROUP NV

ISIN: BE0974281132 WKN: - Asset Class: **Stock**

## Company

2023/09/22 17:35:06



Price

**0.29** EUR

Difference ▲ 1.05%(0.00)



## Contact Details

BIOCARTIS GROUP NV Tel: +32-1-563-26-00  
-- Fax: +  
Generaal de Wittelaan Web:  
11B <http://www.biocartisgroupnv.be>  
2800 Mechelen E-mail: [info@biocartisgroupnv.be](mailto:info@biocartisgroupnv.be)

## Company Profile

Biocartis Group NV engages in the development of personalized medicine for patients around the world. It also focuses on developing and commercializing oncology tests. The company was founded by Philippe Renaud, Nader Donzel, and Rudi Pauwels in July 2007 and is headquartered in Mechelen, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	65,159,000		92,980,000		158,290,000	
<b>Common stock capital</b>		931,000		575,000		575,000
<b>Fixed assets</b>	49,118,000		49,500,000		52,227,000	
<b>Equity capital of a company</b>		-30,284,000		-33,897,000		36,824,000
<b>Cash and cash equivalents</b>	26,125,000		53,522,000		123,668,000	
<b>Accrued liabilities</b>		204,000		75,000		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		42,449,000		33,705,000		29,445,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		102,112,000		142,672,000		144,248,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		149,000		313,000		363,000
<b>Total assets</b>	114,277,000	114,277,000	142,480,000	142,480,000	210,517,000	210,517,000

## Balance notes

	2022	2021	2020
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	526	619	484
<b>Equity ratio</b>	-26.50%	-23.79%	17.49%
<b>Debt-equity ratio</b>	-477.35%	-520.33%	471.68%

## Others

	2022	2021	2020
<b>Tax Expense Rate</b>	0.37%	0.34%	0.36%

# BIOCARTIS GROUP NV

ISIN: BE0974281132 WKN: - Asset Class: **Stock**

## Income statement

	2022	2021	2020
<b>Turnover</b>	57,481,000	48,269,000	43,128,000
<b>Net income</b>	-65,381,000	-71,472,000	-62,934,000
<b>EBIT</b>	-43,558,000	-61,568,000	-48,061,000
<b>Operating income before taxes</b>	-64,737,000	-71,056,000	-62,630,000
<b>Cash Flow</b>	-44,922,000	-65,824,000	-39,304,000
<b>Net interest income</b>	-21,179,000	-9,488,000	-14,569,000
<b>Research and development expenses</b>	35,116,000	43,946,000	40,927,000
<b>Income taxes</b>	-240,000	-243,000	-228,000
<b>Result from investments in subsidiaries, associates and other</b>	-884,000	-659,000	-532,000
<b>Revenues per employee</b>	109,279	77,979	89,107

## Board of Directors

Herman Verrelst	Chairman of Supervisory Board
Bryan DeChairo	Member of Supervisory Board
Christian Reinaldo	Member of Supervisory Board
Christine Kuslich	Member of Supervisory Board
Ann-Christine M. Sundell	Member of Supervisory Board
Luc Gijssens	Member of Supervisory Board

## Members of Management Board

Roger Moody	Chairman of Managing Board
George Cardoza	Member of Executive Committee
Piet Houwen	Member of Executive Committee